104TiP Phase Ib/IIa study of ATR inhibitor tuvusertib + anti-PD-1 cemiplimab in patients with advanced non-squamous (nsq) non-small cell lung cancer (NSCLC) that has progressed on prior anti-PD-(L)1 and platinum-based therapies
Paz-Ares, L., Cappuzzo, F., Yamamoto, N., Vokes, N., Gray, J.E., Owonikoko, T.K., Ariyasu, R., Ishii, H., Kang, J.H., Lee, S-H., Hallwachs, R., Coenen-Stass, A., Sarholz, B., Pudelko, L.A., Mukker, J., Correa, C. Moulin, Gounaris, I., Villaruz, L.
Published in ESMO open (01.03.2024)
Published in ESMO open (01.03.2024)
Get full text
Journal Article